New hope for rare cancer: pill may stall mesothelioma in High-Risk patients
NCT ID NCT05960773
First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 11 times
Summary
This study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have very early-stage mesothelioma. The goal is to see if the drug can stop the cancer from growing or improve it. About 9 participants will receive treatment and be monitored for side effects and progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.